Oncology/Hematology
Myeloma
More in Myeloma
Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches
Study links strong relationships to better physical and emotional outcomes in myeloma care
Longer gaps between anti-BCMA agents associated with improved response rates, study finds
Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma
DREAMM-7 findings help pave the way for Blenrep's return
Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity
Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive
High-fiber diets tied to improved outcomes in stem-cell transplants, slowing myeloma precursors
A drug comeback, new FDA approvals, and a new standard for transplant-ineligible patients
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
High overall response rate, even though many were ineligible for trial leading to drug's approval
